Prediction of response to anti‐vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography‐based machine learning method
- 22 June 2020
- journal article
- research article
- Published by Wiley in Acta Ophthalmologica
- Vol. 99 (1) , E19-E27
Abstract
Purpose: To predict the anti‐vascular endothelial growth factor (VEGF) therapeutic response of diabetic macular oedema (DME) patients from optical coherence tomography (OCT) at the initiation stage of treatment using a machine learning‐based self‐explainable system.Methods: A total of 712 DME patients were included and classified into poor and good responder groups according to central macular thickness decrease after three consecutive injections. Machine learning models were constructed to make predictions based on related features extracted automatically using deep learning algorithms from OCT scans at baseline. Five‐fold cross‐validation was applied to optimize and evaluate the models. The model with the best performance was then compared with two ophthalmologists. Feature importance was further investigated, and a Wilcoxon rank‐sum test was performed to assess the difference of a single feature between two groups.Results: Of 712 patients, 294 were poor responders and 418 were good responders. The best performance for the prediction task was achieved by random forest (RF), with sensitivity, specificity and area under the receiver operating characteristic curve of 0.900, 0.851 and 0.923. Ophthalmologist 1 and ophthalmologist 2 reached sensitivity of 0.775 and 0.750, and specificity of 0.716 and 0.821, respectively. The sum of hyperreflective dots was found to be the most relevant feature for prediction.Conclusion: An RF classifier was constructed to predict the treatment response of anti‐VEGF from OCT images of DME patients with high accuracy. The algorithm contributes to predicting treatment requirements in advance and provides an optimal individualized therapeutic regimen.Keywords
Funding Information
- National Natural Science Foundation of China (81670888)
This publication has 37 references indexed in Scilit:
- Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trialBritish Journal of Ophthalmology, 2012
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- Automatic segmentation of seven retinal layers in SDOCT images congruent with expert manual segmentationOptics Express, 2010
- Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological processActa Ophthalmologica, 2010
- Resource Use and Costs Associated With Diabetic Macular Edema in Elderly PersonsArchives of Ophthalmology (1950), 2008
- Direct and indirect costs among employees with diabetic retinopathy in the United StatesCurrent Medical Research and Opinion, 2008
- Relationship of Glycemic Control, Exogenous Insulin, and C-Peptide Levels to Ischemic Heart Disease Mortality Over a 16-Year Period in People With Older-Onset DiabetesDiabetes Care, 2008
- The economic burden of diabetic retinopathy in Germany in 2002Graefe's Archive for Clinical and Experimental Ophthalmology, 2007
- Epidemiology of diabetic retinopathy and macular oedema: a systematic reviewEye, 2004
- Macular edema. A complication of diabetic retinopathySurvey of Ophthalmology, 1984